References of "Cox, N"
     in
Bookmark and Share    
Full Text
See detailAstrospheres of young and old stars
Cox, N.; Decin, L.; Marle, A.J. et al

Poster (2013, October)

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailMESS (Mass-loss of Evolved StarS), a Herschel Key Program
Groenewegen, M. A. T.; Waelkens, C.; Barlow, M. J. et al

in Astronomy and Astrophysics (2011), 526

MESS (Mass-loss of Evolved StarS) is a Guaranteed Time Key Program that uses the PACS and SPIRE instruments on board the Herschel Space Observatory to observe a representative sample of evolved stars ... [more ▼]

MESS (Mass-loss of Evolved StarS) is a Guaranteed Time Key Program that uses the PACS and SPIRE instruments on board the Herschel Space Observatory to observe a representative sample of evolved stars, that include asymptotic giant branch (AGB) and post-AGB stars, planetary nebulae and red supergiants, as well as luminous blue variables, Wolf-Rayet stars and supernova remnants. In total, of order 150 objects are observed in imaging and about 50 objects in spectroscopy. This paper describes the target selection and target list, and the observing strategy. Key science projects are described, and illustrated using results obtained during Herschel's science demonstration phase. Aperture photometry is given for the 70 AGB and post-AGB stars observed up to October 17, 2010, which constitutes the largest single uniform database of far-IR and sub-mm fluxes for late-type stars. [less ▲]

Detailed reference viewed: 50 (28 ULg)
Full Text
See detailResults from the Herschel Key Program MESS
Groenewegen, M. A. T.; Waelkens, C.; Barlow, M. J. et al

in Kerschbaum, F.; Lebzelter, T.; Wing, R. F. (Eds.) Why Galaxies Care about AGB Stars II: Shining Examples and Common Inhabitants. ASPC 445 (2011)

MESS (Mass loss of Evolved StarS) is a Herschel Guaranteed Time Key Program that will image about 100, and do spectroscopy of about 50, post-main-sequence objects of all flavours: AGB stars, post-AGB ... [more ▼]

MESS (Mass loss of Evolved StarS) is a Herschel Guaranteed Time Key Program that will image about 100, and do spectroscopy of about 50, post-main-sequence objects of all flavours: AGB stars, post-AGB stars, planetary nebulae, luminous blue variables, Wolf-Rayet stars, and supernova remnants. In this review the implementation and current status of MESS is outlined, and first results are presented. [less ▲]

Detailed reference viewed: 44 (27 ULg)
Full Text
Peer Reviewed
See detailA randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis
Kirwan, J. R.; Hallgren, R.; Mielants, H. et al

in Annals of the Rheumatic Diseases (2004), 63(6), 688-695

Objectives: To compare budesonide, a locally acting glucocorticoid with minimal systemic exposure, with conventional glucocorticoid treatment and placebo in rheumatoid arthritis. Methods: A double blind ... [more ▼]

Objectives: To compare budesonide, a locally acting glucocorticoid with minimal systemic exposure, with conventional glucocorticoid treatment and placebo in rheumatoid arthritis. Methods: A double blind, randomised, controlled trial over 12 weeks in 143 patients with active rheumatoid arthritis, comparing budesonide 3 mg daily, budesonide 9 mg daily, prednisolone 7.5 mg daily, and placebo. Particular attention was paid to the pattern of clinical response and to changes in the four week period following discontinuation of treatment. Results: There were improvements in tender joint count and swollen joint count on budesonide 9 mg compared with placebo (28% for tender and 34% for swollen joint counts, p< 0.05). Prednisolone 7.5 mg gave similar results, while budesonide 3 mg was less effective. ACR20 response criteria were met by 25% of patients on placebo, 22% on budesonide 3 mg, 42% on budesonide 9 mg, and 56% on prednisolone 7.5 mg. A rapid and significant reduction in symptoms and signs in response to budesonide 9 mg and prednisolone 7.5 mg was evident by two weeks and maximal at eight weeks. There was no evidence that budesonide provided a different pattern of symptom control from prednisolone, or that symptoms became worse than placebo treatment levels after discontinuation of glucocorticoid treatment. Adverse effects attributable to glucocorticoids were equally common in all groups. Conclusions: The symptomatic benefits of budesonide 9 mg and prednisolone 7.5 mg are achieved within a short time of initiating treatment, are maintained for three months, and are not associated with any rebound in symptoms after stopping treatment. [less ▲]

Detailed reference viewed: 8 (0 ULg)